The dichotomy of tumor exosomes (TEX) in cancer immunity: Is it all in the ConTEXt?

Vaccines

Volumn 3, Issue 4, 2015, Pages 1019-1051

  Kunigelis, Katherine E ^a   Graner, Michael W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presenting cells; B cells; Cancer vaccine; Dendritic cell derived exosomes (DEX); Exosomes microvesicles extracellular vesicles; Immune suppression; Natural killer cells; T cells; Tumor derived exosomes (TEX)

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD1D ANTIGEN; DENDRITIC CELL EXOSOME; DENDRITIC CELL VACCINE; INTERLEUKIN 2; MAGE3 PEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; RITUXIMAB; SIINFEKL PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; EXOSOME; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; METASTATIC MELANOMA; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR DERIVED EXOSOME; TUMOR IMMUNITY; VACCINATION;

EID: 85016912591     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3041019     Document Type: Review

References (166)

1. De Toro, J.; Herschlik, L.; Waldner, C.; Mongini, C. Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications. Front. Immunol. 2015, doi: 10. 3389/fimmu. 2015. 00203.
2. Yanez-Mo, M.; Siljander, P.R.; Andreu, Z.; Zavec, A.B.; Borras, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 2015, doi: 10. 3402/jev. v4. 27066.
3. Benito-Martin, A.; di Giannatale, A.; Ceder, S.; Peinado, H. The new deal: A potential role for secreted vesicles in innate immunity and tumor progression. Front. Immunol. 2015, doi: 10. 3389/fimmu. 2015. 00066.
4. Greening, D.W.; Gopal, S.K.; Xu, R.; Simpson, R.J.; Chen, W. Exosomes and their roles in immune regulation and cancer. Semin. Cell Dev. Biol. 2015, 40, 72-81.
5. Hellwinkel, J.E.; Madsen, H.; Graner, M.W. Immune modulation by tumor-derived extracellular vesicles in glioblastoma. In Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor; Lichtor, T., Ed.; InTech: Rijeka, Croatia, 2015; pp. 329-354.
6. Gould, S.J.; Raposo, G. As we wait: Coping with an imperfect nomenclature for extracellular vesicles. J. Extracell. Vesicles 2013, doi: org/10. 3402/jev. v2i0. 20389.
7. Gyorgy, B.; Szabo, T.G.; Pasztoi, M.; Pal, Z.; Misjak, P.; Aradi, B.; Laszlo, V.; Pallinger, E.; Pap, E.; Kittel, A.; et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011, 68, 2667-2688.
8. Taylor, D.D.; Gercel-Taylor, C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer 2005, 92, 305-311.
9. Cocucci, E.; Meldolesi, J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015, 25, 364-372.
10. Yuana, Y.; Sturk, A.; Nieuwland, R. Extracellular vesicles in physiological and pathological conditions. Blood Rev. 2013, 27, 31-39.
11. Graner, M.W. Brain tumor exosomes and microvesicles: Pleiotropic effects from tiny cellular surrogates. In Molecular Targets of Cns Tumors; Garami, M., Ed.; InTech Open Access: Rijeka, Croatia, 2012.
12. Lin, J.; Li, J.; Huang, B.; Liu, J.; Chen, X.; Chen, X.M.; Xu, Y.M.; Huang, L.F.; Wang, X.Z. Exosomes: Novel biomarkers for clinical diagnosis. Sci. World J. 2015, doi: 10. 1115/2015/657086.
13. Zheng, X.; Chen, F.; Zhang, J.; Zhang, Q.; Lin, J. Exosome analysis: A promising biomarker system with special attention to saliva. J. Membr. Biol. 2014, 247, 1129-1136.
14. Santiago-Dieppa, D.R.; Steinberg, J.; Gonda, D.; Cheung, V.J.; Carter, B.S.; Chen, C.C. Extracellular vesicles as a platform for "liquid biopsy" in glioblastoma patients. Expert Rev. Mol. Diagn. 2014, 14, 819-825.
15. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA.J. Clin. Oncol. 2014, 32, 579-586.
16. Pantel, K.; Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Res. 2013, 73, 6384-6388.
17. Camussi, G.; Deregibus, M.C.; Bruno, S.; Cantaluppi, V.; Biancone, L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010, 78, 838-848.
18. Van Niel, G.; Mallegol, J.; Bevilacqua, C.; Candalh, C.; Brugiere, S.; Tomaskovic-Crook, E.; Heath, J.K.; Cerf-Bensussan, N.; Heyman, M. Intestinal epithelial exosomes carry mhc class ii/peptides able to inform the immune system in mice. Gut 2003, 52, 1690-1697.
19. Chaput, N.; Thery, C. Exosomes: Immune properties and potential clinical implementations. Semin. Immunopathol. 2011, 33, 419-440.
20. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9, 581-593.
21. Zhang, X.; Yuan, X.; Shi, H.; Wu, L.; Qian, H.; Xu, W. Exosomes in cancer: Small particle, big player. J. Hematol. Oncol. 2015, doi: 10. 1093/neuonc/nov170.
22. Miller, I.V.; Grunewald, T.G. Tumour-derived exosomes: Tiny envelopes for big stories. Biol. Cell 2015, 107, 287-305.
23. Lasser, C. Exosomes in diagnostic and therapeutic applications: Biomarker, vaccine and RNA interference delivery vehicle. Expert Opin. Biol. Ther. 2015, 15, 103-117.
24. Redzic, J.S.; Ung, T.H.; Graner, M.W. Glioblastoma extracellular vesicles: Reservoirs of potential biomarkers. Pharmacogen. Personal. Med. 2014, 7, 65-77.
25. Whiteside, T.L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16, 3-15.
26. Hellwinkel, J.E.; Redzic, J.S.; Harland, T.A.; Gunaydin, D.; Anchordoquy, T.J.; Graner, M.W. Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol. 2015, 8, doi: 10. 1093/neuonc/nov170.
27. Steinman, R.M. Decisions about dendritic cells: Past, present, and future. Annu. Rev. Immunol. 2012, doi: 10. 1146/annurev-immunol-100311-102839.
28. Vremec, D.; Shortman, K. What's in a name? Some early and current issues in dendritic cell nomenclature. Front. Immunol. 2015, doi: 10. 3389/fimmu. 2015. 00267.
29. Grakoui, A.; Bromley, S.K.; Sumen, C.; Davis, M.M.; Shaw, A.S.; Allen, P.M.; Dustin, M.L. Pillars article: The immunological synapse: A molecular machine controlling T cell activation. Science. 1999. 285: 221-227. J. Immunol. 2015, 194, 4066-4072.
30. Anguille, S.; Smits, E.L.; Lion, E.; van Tendeloo, V.F.; Berneman, Z.N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014, 15, e257-e267.
31. Carballido, E.; Fishman, M. Sipuleucel-T: Prototype for development of anti-tumor vaccines. Curr. Oncol. Rep. 2011, 13, 112-119.
32. Eyrich, M.; Schreiber, S.C.; Rachor, J.; Krauss, J.; Pauwels, F.; Hain, J.; Wolfl, M.; Lutz, M.B.; de Vleeschouwer, S.; Schlegel, P.G.; et al. Development and validation of a fully gmp-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy 2014, 16, 946-964.
33. Benencia, F.; Sprague, L.; McGinty, J.; Pate, M.; Muccioli, M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J. Biomed. Biotechnol. 2012, doi: 10. 1155/2012/425476.
34. Kurosaki, M.; Horiguchi, S.; Yamasaki, K.; Uchida, Y.; Motohashi, S.; Nakayama, T.; Sugimoto, A.; Okamoto, Y. Migration and immunological reaction after the administration of alphagalcer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol. Immunother. 2011, 60, 207-215.
35. Lesterhuis, W.J.; de Vries, I.J.; Schreibelt, G.; Lambeck, A.J.; Aarntzen, E.H.; Jacobs, J.F.; Scharenborg, N.M.; van de Rakt, M.W.; de Boer, A.J.; Croockewit, S.; et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific t cells in advanced melanoma patients. Clin. Cancer Res. 2011, 17, 5725-5735.
36. Wu, A.A.; Drake, V.; Huang, H.S.; Chiu, S.; Zheng, L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze t cells. Oncoimmunology 2015, 4, e1016700.
37. Katoh, H.; Watanabe, M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediat. inflamm. 2015, doi: 10. 1155/2015/159269.
38. Mao, Y.; Poschke, I.; Kiessling, R. Tumour-induced immune suppression: Role of inflammatory mediators released by myelomonocytic cells. J. Intern. Med. 2014, 276, 154-170.
39. Whiteside, T.L.; Schuler, P.; Schilling, B. Induced and natural regulatory t cells in human cancer. Expert Opin. Biol. Ther. 2012, 12, 1383-1397.
40. Diener, K.R.; Need, E.F.; Buchanan, G.; Hayball, J.D. Tgf-beta signalling and immunity in prostate tumourigenesis. Expert Opin. Ther. Targets 2010, 14, 179-192.
41. Waziri, A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg. Clin. N. Am. 2010, 21, 31-42.
42. Qin, F.X. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol. Immunol. 2009, 6, 3-13.
43. Vega, E.A.; Graner, M.W.; Sampson, J.H. Combating immunosuppression in glioma. Future Oncol. 2008, 4, 433-442.
44. Whiteside, T.L. Immune modulation of T-cell and NK (natural killer) cell activities by texs (tumour-derived exosomes). Biochem. Soc. Trans. 2013, 41, 245-251.
45. Cereghetti, D.M.; Lee, P.P. Tumor-derived exosomes contain micrornas with immunological function: Implications for a novel immunosuppression mechanism. Microrna 2014, 2, 194-204.
46. Raposo, G.; Nijman, H.W.; Stoorvogel, W.; Liejendekker, R.; Harding, C.V.; Melief, C.J.; Geuze, H.J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183, 1161-1172.
47. Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat. Med. 1998, 4, 594-600.
48. Thery, C.; Regnault, A.; Garin, J.; Wolfers, J.; Zitvogel, L.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J. Cell Biol. 1999, 147, 599-610.
49. Tamura, Y.; Torigoe, T.; Kukita, K.; Saito, K.; Okuya, K.; Kutomi, G.; Hirata, K.; Sato, N. Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity. Immunotherapy 2012, 4, 841-852.
50. Gallucci, S.; Matzinger, P. Danger signals: Sos to the immune system. Curr. Opin. Immunol. 2001, 13, 114-119.
51. Seigneuric, R.; Mjahed, H.; Gobbo, J.; Joly, A.L.; Berthenet, K.; Shirley, S.; Garrido, C. Heat shock proteins as danger signals for cancer detection. Front. Oncol. 2011, doi: 10. 3389/fonc. 2011. 00037.
52. Vincent-Schneider, H.; Stumptner-Cuvelette, P.; Lankar, D.; Pain, S.; Raposo, G.; Benaroch, P.; Bonnerot, C. Exosomes bearing hla-dr1 molecules need dendritic cells to efficiently stimulate specific t cells. Int. Immunol. 2002, 14, 713-722.
53. Denzer, K.; van Eijk, M.; Kleijmeer, M.J.; Jakobson, E.; de Groot, C.; Geuze, H.J. Follicular dendritic cells carry mhc class II-expressing microvesicles at their surface. J. Immunol. 2000, 165, 1259-1265.
54. Thery, C.; Duban, L.; Segura, E.; Veron, P.; Lantz, O.; Amigorena, S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 2002, 3, 1156-1162.
55. Andre, F.; Chaput, N.; Schartz, N.E.; Flament, C.; Aubert, N.; Bernard, J.; Lemonnier, F.; Raposo, G.; Escudier, B.; Hsu, D.H.; et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional mhc class I/peptide complexes to dendritic cells. J. Immunol. 2004, 172, 2126-2136.
56. Utsugi-Kobukai, S.; Fujimaki, H.; Hotta, C.; Nakazawa, M.; Minami, M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol. Lett. 2003, 89, 125-131.
57. Sprent, J. Direct stimulation of naive t cells by antigen-presenting cell vesicles. Blood Cells Mol. Dis. 2005, 35, 17-20.
58. Kovar, M.; Boyman, O.; Shen, X.; Hwang, I.; Kohler, R.; Sprent, J. Direct stimulation of T cells by membrane vesicles from antigen-presenting cells. Proc. Natl. Acad. Sci. USA 2006, 103, 11671-11676.
59. Amigorena, S. Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Res. Immunol. 1998, 149, 661-662.
60. Zitvogel, L.; Fernandez, N.; Lozier, A.; Wolfers, J.; Regnault, A.; Raposo, G.; Amigorena, S. Dendritic cells or their exosomes are effective biotherapies of cancer. Eur. J. Cancer 1999, 35, S36-S38.
61. Quah, B.; O'Neill, H.C. Review: The application of dendritic cell-derived exosomes in tumour immunotherapy. Cancer Biother. Radiopharmcol. 2000, 15, 185-194.
62. Chaput, N.; Schartz, N.E.; Andre, F.; Zitvogel, L. Exosomes for immunotherapy of cancer. Adv. Exp. Med. Biol. 2003, 532, 215-221.
63. Andre, F.; Escudier, B.; Angevin, E.; Tursz, T.; Zitvogel, L. Exosomes for cancer immunotherapy. Ann. Oncol. 2004, 15, iv141-iv144.
64. Lamparski, H.G.; Metha-Damani, A.; Yao, J.Y.; Patel, S.; Hsu, D.H.; Ruegg, C.; le Pecq, J.B. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods 2002, 270, 211-226.
65. Morse, M.A.; Garst, J.; Osada, T.; Khan, S.; Hobeika, A.; Clay, T.M.; Valente, N.; Shreeniwas, R.; Sutton, M.A.; Delcayre, A.; et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 2005, doi: 10. 1186/1479-5876-3-9.
66. Escudier, B.; Dorval, T.; Chaput, N.; Andre, F.; Caby, M.P.; Novault, S.; Flament, C.; Leboulaire, C.; Borg, C.; Amigorena, S.; et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst phase I clinical trial. J. Transl. Med. 2005, doi: 10. 1186/1479-5876-3-10.
67. Viaud, S.; Terme, M.; Flament, C.; Taieb, J.; Andre, F.; Novault, S.; Escudier, B.; Robert, C.; Caillat-Zucman, S.; Tursz, T.; et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: A role for NKG2D ligands and IL-15ralpha. PLoS ONE 2009, 4, e4942.
68. Viaud, S.; Thery, C.; Ploix, S.; Tursz, T.; Lapierre, V.; Lantz, O.; Zitvogel, L.; Chaput, N. Dendritic cell-derived exosomes for cancer immunotherapy: What's next? Cancer Res. 2010, 70, 1281-1285.
69. Narita, M.; Kanda, T.; Abe, T.; Uchiyama, T.; Iwafuchi, M.; Zheng, Z.; Liu, A.; Kaifu, T.; Kosugi, S.; Minagawa, M.; et al. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. Int. J. Oncol. 2015, 46, 1699-1709.
70. Pitt, J.M.; Charrier, M.; Viaud, S.; Andre, F.; Besse, B.; Chaput, N.; Zitvogel, L. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J. Immunol. 2014, 193, 1006-1011.
71. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015, 27, 450-461.
72. Naslund, T.I.; Gehrmann, U.; Qazi, K.R.; Karlsson, M.C.; Gabrielsson, S. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 2013, 190, 2712-2719.
73. Gehrmann, U.; Hiltbrunner, S.; Georgoudaki, A.M.; Karlsson, M.C.; Naslund, T.I.; Gabrielsson, S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes. Cancer Res. 2013, 73, 3865-3876.
74. Srivatsan, S.; Patel, J.M.; Bozeman, E.N.; Imasuen, I.E.; He, S.; Daniels, D.; Selvaraj, P. Allogeneic tumor cell vaccines: The promise and limitations in clinical trials. Hum. Vaccines Immunother. 2014, 10, 52-63.
75. Guan, S.; Li, Q.; Liu, P.; Xuan, X.; Du, Y. Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo. Cent. Eur. J. Immunol. 2014, 39, 142-151.
76. Bu, N.; Wu, H.; Zhang, G.; Ma, X.; Zhao, P.; Zhai, N.; Xiang, L.; Cao, H.; Yang, X.; Liu, J. Exosome from chaperone-rich cell lysates-loaded dendritic cells produced by celline 1000 culture system exhibits potent immune activity. Biochem. Biophys. Res. Commun. 2015, 456, 513-518.
77. Graner, M.; Raymond, A.; Akporiaye, E.; Katsanis, E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 2000, 49, 476-484.
78. Graner, M.W.; Zeng, Y.; Feng, H.; Katsanis, E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 2003, 52, 226-234.
79. Graner, M.W.; Romanoski, A.; Katsanis, E. The "peptidome" of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int. J. Hyperth. 2013, 29, 380-389.
80. Epple, L.M.; Bemis, L.T.; Cavanaugh, R.P.; Skope, A.; Mayer-Sonnenfeld, T.; Frank, C.; Olver, C.S.; Lencioni, A.M.; Dusto, N.L.; Tal, A.; et al. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int. J. Hyperthermia 2013, 29, 390-398.
81. Mayer-Sonnenfeld, T.; Har-Noy, M.; Lillehei, K.O.; Graner, M.W. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for crcl's unique structure: Crcl vaccine proteome leads to unique structure. Int. J. Hyperthermia 2013, 29, 520-527.
82. Bu, N.; Wu, H.; Zhang, G.; Zhan, S.; Zhang, R.; Sun, H.; Du, Y.; Yao, L.; Wang, H. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent t cell immune response against intracranial glioma in mice. J. Mol. Neurosci. 2015, 56, 631-643.
83. Romagnoli, G.G.; Zelante, B.B.; Toniolo, P.A.; Migliori, I.K.; Barbuto, J.A. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front. Immunol. 2014, doi: 10. 3389/fimmu. 2014. 00692.
84. Wolfers, J.; Lozier, A.; Raposo, G.; Regnault, A.; Thery, C.; Masurier, C.; Flament, C.; Pouzieux, S.; Faure, F.; Tursz, T.; et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for ctl cross-priming. Nat. Med. 2001, 7, 297-303.
85. Altieri, S.L.; Khan, A.N.; Tomasi, T.B. Exosomes from plasmacytoma cells as a tumor vaccine. J. Immunother. 2004, 27, 282-288.
86. Andre, F.; Schartz, N.E.; Chaput, N.; Flament, C.; Raposo, G.; Amigorena, S.; Angevin, E.; Zitvogel, L. Tumor-derived exosomes: A new source of tumor rejection antigens. Vaccine 2002, 20, A28-A31.
87. Lee, E.Y.; Park, K.S.; Yoon, Y.J.; Lee, J.; Moon, H.G.; Jang, S.C.; Choi, K.H.; Kim, Y.K.; Gho, Y.S. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE 2012, 7, e33330.
88. Bu, N.; Li, Q.L.; Feng, Q.; Sun, B.Z. Immune protection effect of exosomes against attack of L1210 tumor cells. Leuk. Lymphoma 2006, 47, 913-918.
89. Graner, M.W.; Cumming, R.I.; Bigner, D.D. The heat shock response and chaperones/heat shock proteins in brain tumors: Surface expression, release, and possible immune consequences. J. Neurosci. 2007, 27, 11214-11227.
90. Graner, M.W.; Alzate, O.; Dechkovskaia, A.M.; Keene, J.D.; Sampson, J.H.; Mitchell, D.A.; Bigner, D.D. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009, 23, 1541-1557.
91. Mulcahy, L.A.; Pink, R.C.; Carter, D.R. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 2014, 3, doi: 10. 3402/jev. v3. 24641.
92. Hao, S.; Bai, O.; Yuan, J.; Qureshi, M.; Xiang, J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTLresponses and antitumor immunity than tumor cell-derived exosomes. Cell Mol. Immunol. 2006, 3, 205-211.
93. Gu, X.; Erb, U.; Buchler, M.W.; Zoller, M. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 2015, 136, E74-E84.
94. Dai, S.; Wan, T.; Wang, B.; Zhou, X.; Xiu, F.; Chen, T.; Wu, Y.; Cao, X. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed cea-positive tumor cells. Clin. Cancer Res. 2005, 11, 7554-7563.
95. Cho, J.A.; Lee, Y.S.; Kim, S.H.; Ko, J.K.; Kim, C.W. Mhc independent anti-tumor immune responses induced by hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2009, 275, 256-265.
96. Xie, Y.; Bai, O.; Zhang, H.; Yuan, J.; Zong, S.; Chibbar, R.; Slattery, K.; Qureshi, M.; Wei, Y.; Deng, Y.; et al. Membrane-bound hsp70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) ctl-and nk-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic hsp70. J. Cell. Mol. Med. 2010, 14, 2655-2666.
97. Chen, T.; Guo, J.; Yang, M.; Zhu, X.; Cao, X. Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J. Immunol. 2011, 186, 2219-2228.
98. Yang, Y.; Xiu, F.; Cai, Z.; Wang, J.; Wang, Q.; Fu, Y.; Cao, X. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J. Cancer Res. Clin. Oncol. 2007, 133, 389-399.
99. Xie, Y.; Bai, O.; Zhang, H.; Li, W.; Xiang, J. Tumor necrosis factor gene-engineered j558 tumor cell-released exosomes stimulate tumor antigen p1a-specific CD8+ ctl responses and antitumor immunity. Cancer Biother. Radiopharm. 2010, 25, 21-28.
100. Lee, Y.S.; Kim, S.H.; Cho, J.A.; Kim, C.W. Introduction of the ciita gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp. Mol. Med. 2011, 43, 281-290.
101. Rountree, R.B.; Mandl, S.J.; Nachtwey, J.M.; Dalpozzo, K.; Do, L.; Lombardo, J.R.; Schoonmaker, P.L.; Brinkmann, K.; Dirmeier, U.; Laus, R.; et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011, 71, 5235-5244.
102. Zeelenberg, I.S.; van Maren, W.W.; Boissonnas, A.; van Hout-Kuijer, M.A.; den Brok, M.H.; Wagenaars, J.A.; van der Schaaf, A.; Jansen, E.J.; Amigorena, S.; Thery, C.; et al. Antigen localization controls T cell-mediated tumor immunity. J. Immunol. 2011, 187, 1281-1288.
103. Sedlik, C.; Vigneron, J.; Torrieri-Dramard, L.; Pitoiset, F.; Denizeau, J.; Chesneau, C.; de la Rochere, P.; Lantz, O.; Thery, C.; Bellier, B. Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms. J. Extracell. Vesicles 2014, doi: 10. 3402/jev. v3. 24646.
104. Hartman, Z.C.; Wei, J.; Glass, O.K.; Guo, H.; Lei, G.; Yang, X.Y.; Osada, T.; Hobeika, A.; Delcayre, A.; le Pecq, J.B.; et al. Increasing vaccine potency through exosome antigen targeting. Vaccine 2011, 29, 9361-9367.
105. Zeelenberg, I.S.; Ostrowski, M.; Krumeich, S.; Bobrie, A.; Jancic, C.; Boissonnas, A.; Delcayre, A.; le Pecq, J.B.; Combadiere, B.; Amigorena, S.; et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res. 2008, 68, 1228-1235.
106. Xiu, F.; Cai, Z.; Yang, Y.; Wang, X.; Wang, J.; Cao, X. Surface anchorage of superantigen sea promotes induction of specific antitumor immune response by tumor-derived exosomes. J. Mol. Med. 2007, 85, 511-521.
107. Dai, S.; Wei, D.; Wu, Z.; Zhou, X.; Wei, X.; Huang, H.; Li, G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 2008, 16, 782-790.
108. Graner, M.W.; Bigner, D.D. Chaperone proteins and brain tumors: Potential targets and possible therapeutics. Neuro Oncol. 2005, 7, 260-278.
109. Graner, M.W.; Bigner, D.D. Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. Expert Rev. Anticancer Ther. 2006, 6, 679-695.
110. Toraya-Brown, S.; Fiering, S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int. J. Hyperth. 2014, 30, 531-539.
111. Jego, G.; Hazoume, A.; Seigneuric, R.; Garrido, C. Targeting heat shock proteins in cancer. Cancer Lett. 2013, 332, 275-285.
112. Lv, L.H.; Wan, Y.L.; Lin, Y.; Zhang, W.; Yang, M.; Li, G.L.; Lin, H.M.; Shang, C.Z.; Chen, Y.J.; Min, J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J. Biol. Chem. 2012, 287, 15874-15885.
113. Xiao, W.; Dong, W.; Zhang, C.; Saren, G.; Geng, P.; Zhao, H.; Li, Q.; Zhu, J.; Li, G.; Zhang, S.; et al. Effects of the epigenetic drug ms-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. Eur. J. Med. Res. 2013, 18, doi: 10. 1186/2047-783X-18-61.
114. Mincheva-Nilsson, L.; Baranov, V. Cancer exosomes and NKG2D receptor-ligand interactions: Impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin. Cancer Biol. 2014, 28, 24-30.
115. Parmiani, G.; Rodolfo, M.; Melani, C. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal. Hum. Gene Ther. 2000, 11, 1269-1275.
116. Zhang, J.; Zhang, Y.; Luo, C.; Xia, Y.; Chen, H.; Wu, X. Glycosyl-phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro. Tumori 2010, 96, 452-459.
117. Napoletano, C.; Rughetti, A.; Landi, R.; Pinto, D.; Bellati, F.; Rahimi, H.; Spinelli, G.P.; Pauselli, S.; Sale, P.; Dolo, V.; et al. Immunogenicity of allo-vesicle carrying ErbB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy. Int. J. Immunopathol. Pharmacol. 2009, 22, 647-658.
118. Delcayre, A.; Estelles, A.; Sperinde, J.; Roulon, T.; Paz, P.; Aguilar, B.; Villanueva, J.; Khine, S.; le Pecq, J.B. Exosome display technology: Applications to the development of new diagnostics and therapeutics. Blood Cells Mol. Dis. 2005, 35, 158-168.
119. Adams, M.; Navabi, H.; Croston, D.; Coleman, S.; Tabi, Z.; Clayton, A.; Jasani, B.; Mason, M.D. The rationale for combined chemo/immunotherapy using a toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 2005, 23, 2374-2378.
120. Andre, F.; Schartz, N.E.; Movassagh, M.; Flament, C.; Pautier, P.; Morice, P.; Pomel, C.; Lhomme, C.; Escudier, B.; le Chevalier, T.; et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360, 295-305.
121. Navabi, H.; Croston, D.; Hobot, J.; Clayton, A.; Zitvogel, L.; Jasani, B.; Bailey-Wood, R.; Wilson, K.; Tabi, Z.; Mason, M.D.; et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol. Dis. 2005, 35, 149-152.
122. Liu, Y.; Gu, Y.; Cao, X. The exosomes in tumor immunity. Oncoimmunology 2015, 4, e1027472.
123. Robbins, P.D.; Morelli, A.E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 2014, 14, 195-208.
124. Zhang, H.G.; Zhuang, X.; Sun, D.; Liu, Y.; Xiang, X.; Grizzle, W.E. Exosomes and immune surveillance of neoplastic lesions: A review. Biotech. Histochem. 2012, 87, 161-168.
125. Valenti, R.; Huber, V.; Iero, M.; Filipazzi, P.; Parmiani, G.; Rivoltini, L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007, 67, 2912-2915.
126. Andreola, G.; Rivoltini, L.; Castelli, C.; Huber, V.; Perego, P.; Deho, P.; Squarcina, P.; Accornero, P.; Lozupone, F.; Lugini, L.; et al. Induction of lymphocyte apoptosis by tumor cell secretion of fasl-bearing microvesicles. J. Exp. Med. 2002, 195, 1303-1316.
127. Kim, J.W.; Wieckowski, E.; Taylor, D.D.; Reichert, T.E.; Watkins, S.; Whiteside, T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005, 11, 1010-1020.
128. Abusamra, A.J.; Zhong, Z.; Zheng, X.; Li, M.; Ichim, T.E.; Chin, J.L.; Min, W.P. Tumor exosomes expressing fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol. Dis. 2005, 35, 169-173.
129. Ichim, T.E.; Zhong, Z.; Kaushal, S.; Zheng, X.; Ren, X.; Hao, X.; Joyce, J.A.; Hanley, H.H.; Riordan, N.H.; Koropatnick, J.; et al. Exosomes as a tumor immune escape mechanism: Possible therapeutic implications. J. Transl. Med. 2008, doi: 10. 1186/1479-5876-6-37.
130. Clayton, A.; Al-Taei, S.; Webber, J.; Mason, M.D.; Tabi, Z. Cancer exosomes express CD39 and CD73, which suppress t cells through adenosine production. J. Immunol. 2011, 187, 676-683.
131. Clayton, A.; Mitchell, J.P.; Court, J.; Mason, M.D.; Tabi, Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007, 67, 7458-7466.
132. Szajnik, M.; Czystowska, M.; Szczepanski, M.J.; Mandapathil, M.; Whiteside, T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 2010, 5, e11469.
133. Battke, C.; Ruiss, R.; Welsch, U.; Wimberger, P.; Lang, S.; Jochum, S.; Zeidler, R. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol. Immunother. 2011, 60, 639-648.
134. Aung, T.; Chapuy, B.; Vogel, D.; Wenzel, D.; Oppermann, M.; Lahmann, M.; Weinhage, T.; Menck, K.; Hupfeld, T.; Koch, R.; et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc. Natl. Acad. Sci. USA 2011, 108, 15336-15341.
135. Graner, M.W.; Epple, L.M.; Dusto, N.L.; Lencioni, A.M.; Nega, M.; Herring, M.; Winston, B.; Madsen, H.; Bemis, L.T.; Anchordoquy, T.J. Circulating exosomes as new biomarkers for brain disease and injury. In Proceedings of SPIE Vol. 8723 Sensing Technologies for Global Health, Military Medicine, and Environmental Monitoring III; Baltimore, MD, USA, 29 Apr-1 May 2013; Southern, S.O., Ed.
136. Clayton, A.; Tabi, Z. Exosomes and the mica-NKG2D system in cancer. Blood Cells Mol. Dis. 2005, 34, 206-213.
137. Szczepanski, M.J.; Szajnik, M.; Welsh, A.; Whiteside, T.L.; Boyiadzis, M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011, 96, 1302-1309.
138. Clayton, A.; Mitchell, J.P.; Court, J.; Linnane, S.; Mason, M.D.; Tabi, Z. Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 2008, 180, 7249-7258.
139. Hedlund, M.; Nagaeva, O.; Kargl, D.; Baranov, V.; Mincheva-Nilsson, L. Thermal-and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma t and b cells. PLoS ONE 2011, 6, e16899.
140. Gastpar, R.; Gehrmann, M.; Bausero, M.A.; Asea, A.; Gross, C.; Schroeder, J.A.; Multhoff, G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005, 65, 5238-5247.
141. Elsner, L.; Muppala, V.; Gehrmann, M.; Lozano, J.; Malzahn, D.; Bickeboller, H.; Brunner, E.; Zientkowska, M.; Herrmann, T.; Walter, L.; et al. The heat shock protein hsp70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J. Immunol. 2007, 179, 5523-5533.
142. Yu, S.; Liu, C.; Su, K.; Wang, J.; Liu, Y.; Zhang, L.; Li, C.; Cong, Y.; Kimberly, R.; Grizzle, W.E.; et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 2007, 178, 6867-6875.
143. Xiang, X.; Poliakov, A.; Liu, C.; Liu, Y.; Deng, Z.B.; Wang, J.; Cheng, Z.; Shah, S.V.; Wang, G.J.; Zhang, L.; et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124, 2621-2633.
144. Chalmin, F.; Ladoire, S.; Mignot, G.; Vincent, J.; Bruchard, M.; Remy-Martin, J.P.; Boireau, W.; Rouleau, A.; Simon, B.; Lanneau, D.; et al. Membrane-associated hsp72 from tumor-derived exosomes mediates stat3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Investig. 2010, 120, 457-471.
145. Chow, A.; Zhou, W.; Liu, L.; Fong, M.Y.; Champer, J.; van Haute, D.; Chin, A.R.; Ren, X.; Gugiu, B.G.; Meng, Z.; et al. Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappab. Sci. Rep. 2014, doi: 10. 1038/srep05750.
146. De Vrij, J.; Maas, S.L.; Kwappenberg, K.M.; Schnoor, R.; Kleijn, A.; Dekker, L.; Luider, T.M.; de Witte, L.D.; Litjens, M.; van Strien, M.E.; et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int. J. Cancer 2015, 137, 1630-1642.
147. Marton, A.; Vizler, C.; Kusz, E.; Temesfoi, V.; Szathmary, Z.; Nagy, K.; Szegletes, Z.; Varo, G.; Siklos, L.; Katona, R.L.; et al. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunol. Lett. 2012, 148, 34-38.
148. He, M.; Qin, H.; Poon, T.C.; Sze, S.C.; Ding, X.; Co, N.N.; Ngai, S.M.; Chan, T.F.; Wong, N. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and rnas. Carcinogenesis 2015, 36, 1008-1018.
149. Melo, S.A.; Sugimoto, H.; O'Connell, J.T.; Kato, N.; Villanueva, A.; Vidal, A.; Qiu, L.; Vitkin, E.; Perelman, L.T.; Melo, C.A.; et al. Cancer exosomes perform cell-independent microrna biogenesis and promote tumorigenesis. Cancer Cell 2014, 26, 707-721.
150. Ye, S.B.; Li, Z.L.; Luo, D.H.; Huang, B.J.; Chen, Y.S.; Zhang, X.S.; Cui, J.; Zeng, Y.X.; Li, J. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal micrornas in human nasopharyngeal carcinoma. Oncotarget 2014, 5, 5439-5452.
151. Yu, D.D.; Wu, Y.; Shen, H.Y.; Lv, M.M.; Chen, W.X.; Zhang, X.H.; Zhong, S.L.; Tang, J.H.; Zhao, J.H. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 2015, 106, 959-964.
152. Scheerlinck, J.P.; Greenwood, D.L. Virus-sized vaccine delivery systems. Drug Discov. Today 2008, 13, 882-887.
153. Lattanzi, L.; Federico, M. A strategy of antigen incorporation into exosomes: Comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles. Vaccine 2012, 30, 7229-7237.
154. Smyth, T.J.; Redzic, J.S.; Graner, M.W.; Anchordoquy, T.J. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim. Biophys. Acta 2014, 1838, 2954-2965.
155. Smyth, T.; Petrova, K.; Payton, N.M.; Persaud, I.; Redzic, J.S.; Graner, M.W.; Smith-Jones, P.; Anchordoquy, T.J. Surface functionalization of exosomes using click chemistry. Bioconjugate Chem. 2014, 25, 1777-1784.
156. Gyorgy, B.; Hung, M.E.; Breakefield, X.O.; Leonard, J.N. Therapeutic applications of extracellular vesicles: Clinical promise and open questions. Annu. Rev. Pharmacol. Toxicol. 2015, 55, 439-464.
157. Gehrmann, U.; Naslund, T.I.; Hiltbrunner, S.; Larssen, P.; Gabrielsson, S. Harnessing the exosome-induced immune response for cancer immunotherapy. Semin. Cancer Biol. 2014, 28, 58-67.
158. Barua, S.; Mitragotri, S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. Nano Today 2014, 9, 223-243.
159. Kim, S.H.; Bianco, N.; Menon, R.; Lechman, E.R.; Shufesky, W.J.; Morelli, A.E.; Robbins, P.D. Exosomes derived from genetically modified dc expressing fasl are anti-inflammatory and immunosuppressive. Mol. Ther. 2006, 13, 289-300.
160. Segura, E.; Guerin, C.; Hogg, N.; Amigorena, S.; Thery, C. CD8+ dendritic cells use lfa-1 to capture MHC-peptide complexes from exosomes in vivo. J. Immunol. 2007, 179, 1489-1496.
161. Iero, M.; Valenti, R.; Huber, V.; Filipazzi, P.; Parmiani, G.; Fais, S.; Rivoltini, L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008, 15, 80-88.
162. Bai, J.; Xie, X.; Lei, Y.; An, G.; He, L.; Chen, R. Consideration of dual characters of exosomes in the tumour immune response. Cell Biol. Int. 2014, 38, 538-545.
163. Lu, M.; Huang, B.; Hanash, S.M.; Onuchic, J.N.; Ben-Jacob, E. Modeling putative therapeutic implications of exosome exchange between tumor and immune cells. Proc. Natl. Acad. Sci. USA 2014, 111, E4165-E4174.
164. Marleau, A.M.; Chen, C.S.; Joyce, J.A.; Tullis, R.H. Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med. 2012, doi: 10. 1186/1479-5876-10-134.
165. Podack, E.R.; Raez, L.E. Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96. Expert Opin. Biol. Ther. 2007, 7, 1679-1688.
166. Ito, A.; Kondo, S.; Tada, K.; Kitano, S. Clinical development of immune checkpoint inhibitors. BioMed Res. Int. 2015, doi: 10. 1155/2015/605478.